AbbVie Inc. (ABBV)
AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide.
Scored against other Healthcare stocks, not a fixed scale.
The quick read
AbbVie reads as neutral right now, with no clear lean either way.
- What's working
- Its price has held up well, trading above its recent averages.
- Worth watching
- It carries more debt, or less cash, than most other healthcare companies.
Analyst price target
~12-month · 28 analystsPublished targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
About AbbVie Inc.
AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide…
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Employees
- 57,000
- Headquarters
- North Chicago, IL
Similar stocks
What’s behind the score
Valuation
P/E 80.6 — lower than 4% of Healthcare peers
P/S 7.8 — lower than 17% of Healthcare peers
EV/EBITDA 18.5 — lower than 30% of Healthcare peers
EV/Revenue 8.8 — lower than 17% of Healthcare peers
PEG 0.6 — lower than 93% of Healthcare peers
FCF yield 3.3% — higher than 34% of Healthcare peers
Profitability & quality
Gross margin 72.8% — higher than 80% of Healthcare peers
Operating margin 40.0% — higher than 97% of Healthcare peers
Net margin 9.8% — higher than 47% of Healthcare peers
ROA 10.5% — higher than 72% of Healthcare peers
Free cash flow is 269% of reported net income
Financial health
Current ratio 0.81 — higher than 7% of Healthcare peers
Quick ratio 0.49 — higher than 10% of Healthcare peers
Cash/debt 0.09 — higher than 17% of Healthcare peers
Debt/EBITDA 2.30 — lower than 55% of Healthcare peers
Growth
Revenue growth 10.2% YoY — higher than 67% of Healthcare peers
Earnings growth 290.4% YoY — higher than 100% of Healthcare peers
Ownership & investor activity
Payout ratio 190.4% — atypical vs Healthcare peers
Net insider buying, +0.6% of insider shares
Institutions net sold, -12.7% of shares held
Insiders hold 0.1% of shares outstanding
1.0% of float sold short
Momentum
Above its 50- & 200-day averages
94% of the way from its 52-week low to high